CEACAM5 and non-small cell lung carcinoma: Carcinoembryonic antigen (CEA) and cytokeratin-19 fragment (CYFRA 21-1), which have been used for decades to monitor the efficacy of antitumor therapy, may also be useful in predicting NSCLC patient outcome (63, 64).